Introduction
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for the expanding population of patients with advanced stage heart failure. Clinical experience and technology advancements have contributed to a gradual improvement in survival and quality of life in patients supported by these devices.
1,2 Further advancement in LVAD technology warrants optimization of the patient-device interface to minimize the effects of momentous adverse events. Primarily, it is crucial to alleviate thrombotic and haemorrhagic complications of implantable LVADs. The HeartMate 3 Left Ventricular Assist System (LVAS) (Abbott, Abbott Park, IL, USA) represents an innovation in LVAD technology, with design characteristics that may provide incremental advantage in minimizing adverse haemocompatibility-related responses. 3 This system includes a fully magnetically levitated rotor to eliminate wear and heat generation, wide blood flow gaps for minimal shear stress on blood components, textured blood-contacting surfaces for establishing a biologic interface between the implant and blood, and an artificial pulse to avoid blood stasis. Initial studies support the notion that improved haemocompatibility has been achieved, with fewer related adverse events, 4 enhanced preservation of von Willebrand high-molecular-weight multimers, 5 and the absence of pump thrombosis events. 6 Since the first-in-man implantation of the HeartMate 3 was performed in 2014 at Hannover Medical School, 50 patients were enrolled in the Conformité Européenne (CE) mark clinical trial who were implanted with the HeartMate 3 for either bridge to transplant (BTT) or destination therapy (DT). 6 -9 The majority of HeartMate 3 patients experienced substantial improvement in functional status and quality of life. The operative mortality, postoperative bleeding, and infection rates were low compared to other studies, while there have been no cases of pump thrombosis, pump failure, or haemolysis up to 1 year of support. 6 On the basis of 6-month results, CE-mark approval was obtained in October 2015; the planned 2-year follow-up has now been completed, and we present the pre-specified analysis and results.
Methods
This multicentre, prospective, non-randomized, single-arm study was completed at 10 medical centres in six countries. The study protocol was reviewed and approved by the respective regulatory agencies and ethics committees for each participating centre. All participants met the study inclusion criteria and provided informed consent. Details of the study protocol, a description of the HeartMate 3 LVAS, and detailed implantation procedures have been previously described. 3,7 -10 Implantation was accomplished through median sternotomy with cardiopulmonary bypass support. The pump is positioned at the left ventricular apex with the inflow conduit inserted into the left ventricle and the outflow graft anastomosed end-to-side to the ascending aorta.
Candidates for the study were adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure, with an ejection fraction ≤25%, and a cardiac index ≤2.2 L/min/m 2 without inotropic support, or inotrope-dependent patients with optimal medical management, or listed for heart transplant. Enrolled patients included those designated for BTT and DT indications. The primary endpoint of the study was survival at 6 months compared with a performance goal of 88%. The 2-year follow-up included outcomes (transplant, death, explant, ongoing support), adverse event rates (INTERMACS-defined), quality of life (EuroQol; EQ-5D-5 L), functional status (NYHA class, six-minute walk), incidence of device failure, . Guidelines for anticoagulation therapy included intravenous heparin once chest tube drainage was <50 mL/h for 3 h, with the goal of a partial thromboplastin time of 45 to 65 s. The heparin dose was increased over 2 days to reach a partial thromboplastin time of 55 to 65 s. Aspirin (81 to 100 mg daily) and warfarin (or other vitamin K antagonist) were begun once the patient was able to take oral medications; this regimen was continued throughout support, with a target international normalized ratio (INR) of 2.0 to 3.0.
The clinical trial protocol was developed and sponsored by Abbott. Ten participating centres enrolled patients, implanted the device, managed care of the patients, and reported study data to the sponsor. The study sponsor managed the protocol, audited the data, and provided statistical analysis.
Continuous variables are presented as number of subjects, mean ± standard deviation, or median and range when appropriate. Categorical variables are reported as frequencies and percentages. Survival data are presented using the Kaplan-Meier method, and competing outcomes at the 2-year time point are presented. Adverse event data are given as number and percentage of patients with the event. Two-tailed t-test results were considered significant when P < 0.05.
Results
Fifty patients were enrolled in the study from June 2014 to November 2014, with the 2-year follow-up completed in December 2016. Demographics and preoperative heart failure status for the enrolled patients are listed in Table 1 . Before implantation, the mean cardiac index was 1.8 ±0.5 L/min/m 2 , 46 patients (92%) were classified as INTERMACS profiles 2-4, and 58% were receiving inotropic support. The indications for LVAD support were BTT (54%) and DT (46%).
Outcomes
The 6-month, 1-year, and 2-year survival rates were 92 ± 4%, 81 ± 6%, and 74 ± 6%, respectively ( Figure 1) . The median duration of support at the 2-year follow-up was 694 days (range: 19-833 days), with 32 (64%) of the patients continuing with device support (Figure 2 ). Five (10%) patients underwent heart transplant at 50, 101, 231, 501, and 646 days after device implant. One patient (2%) had the device explanted on postoperative day 185 due to sepsis. Twelve deaths (24%) occurred, caused by stroke (n = 4; 8%), multiple organ failure (n = 2; 4%), sepsis (n = 2; 4%), suicide (n = 1; 2%), anaphylaxis (n = 1; 2%), oesophageal bleeding (n = 1; 2%), and disseminated skin cancer (n = 1; 2%).
Of the 44 patients that were discharged from the hospital with HeartMate 3 support, 35 patients (80% of the discharged patients) had a total of 104 readmissions over the 2-year follow-up time. Nine of these patients (20.5%) did not require any readmissions, whereas 9 (20.5%) required one readmission and 26 (59.1%) were readmitted two or more times over the 2 years. Of 104 readmissions, the vast majority (n = 83) were for adverse events, eight were for routine testing or transplant evaluation, one was for observation after malfunction of a battery clip, and 12 were for various other reasons. The two main adverse events that caused rehospitalization were infection and bleeding, both of which were recurrent in some patients ( Table 2) . For the six patients not discharged from the hospital, five died and one underwent transplant during the index hospitalization.
Adverse events
Adverse events are reported with respect to the day post-implant-0 to 180 days, 181 to 365 days, and 366 to 730 days-and the total for the 2 years ( Table 3 ). There were no cases of pump malfunction, pump thrombosis, or haemolysis during the 2-year follow-up. The majority of adverse events occurred within the first 6 months of support and decreased in frequency thereafter. Bleeding and infection were the most common adverse events. The overall bleeding rate declined 20% from the first 6 months to the second 6 months, whereas the rate of gastrointestinal bleeding remained fairly constant over the 2 years. The frequency of sepsis was 16% in the first 6 months, with no cases reported in the second year. The frequency of driveline infection was nearly equal during all follow-up times. The rate of stroke was highest during the first 6 months (12%), then decreased to 7% in the second 6 months, and the rate was 8% . in the second year. The total stroke rate for the entire follow-up time was 24%-0.15 events per patient-year. The freedom from debilitating stroke (modified Rankin score > 3) was 84.9 ± 5% at 1 year and 77.3 ± 6% at 2 years. There were no pump malfunctions over the 2-year follow-up; however, there was a total of 19 system-component-related events that did not result in failure to support the patients. These included three events related to the apical cuff assembly, one with the sealed outflow graft, and 15 events related to the HeartMate 3 specific external system components. The three apical cuff assembly events occurred with the original version of the apical cuff and resulted in difficulty engaging sliding lock of the pump to the apical cuff. Two of these events were resolved by the surgeon and one was a serious event, requiring replacement of the cuff due to bleeding; this patient was diagnosed with an ischaemic stroke (presumably air embolism) on postoperative day 1 and, thereafter, expired on day 19. A sealed outflow graft malfunction was reported in association with thrombus formation. The intraluminal thrombus was discovered on post-implant day 209 during workup for acute onset of sepsis. The thrombus embolized 
ICD, implantable cardioverter-defibrillator.
before the planned surgical exchange, resulting in an ischaemic stroke, which then caused the fatality. The external component malfunctions included 12 controller malfunctions that required exchange of the controller, two modular cable replacements, and one tunnelling adapter complaint.
Quality of life and physical functioning
Quality of life assessed by the EuroQol visual analogue score showed significant improvement from baseline to 6 months (P < 0.0001) and was sustained to 24 months ( Figure 3A) . At baseline, all patients were in NYHA functional class IIIB or IV. At 2 years, 88% of patients were classified as NYHA class I or II (P < 0.0001), with no patients reported as NYHA class IV. Results of the six-minute walk test showed significant early improvement, which was sustained to 24 months after implant ( Figure 3B ).
Discussion
The outcomes and adverse event rates previously reported at 6 months and 1 year are maintained at 2 years. Notably, the absence of haemolysis and pump thrombosis was preserved over the 2-year follow-up. (Figure 4) . 11 -13 At baseline, the entire patient cohort comprised of end-stage heart failure patients classified as NYHA class IIIB or IV, and there was significant and sustained improvement in functional capacity and quality of life over the 2 years.
Pump thrombosis is a key adverse event associated with LVAD implantation, with considerable associated morbidity.
14,15 Most patients may survive this event by undergoing device exchange or, less frequently, with thrombolytic therapy. Pump exchange can be performed relatively safely; however, at the expense of morbidity due to major surgery and considerable cost.
16 -18 Reported rates of pump thrombosis for patients implanted with most commonly used LVADs are 6% to 12% for the HeartMate II LVAS (Abbott) and 8% for the HeartWare HVAD (Medtronic, Framingham, MA, USA) at 1 year, respectively. 14, 19, 20 In the ENDURANCE trial, the 2-year pump thrombosis rates were 10.7% for the HeartMate II and 6.4% for the HVAD. 21 Two-year data from this study continue to show no cases of pump thrombosis. The single case of outflow graft thrombosis observed in this study is believed to be related to sepsis rather than thrombogenicity of the device. The absence of pump thrombosis observed in this study is further supported by the absence of this adverse event in the larger MOMENTUM 3 trial.
13,22

Gastrointestinal bleeding
The occurrence of gastrointestinal (GI) bleeding during LVAD support is one principal complication leading to rehospitalization and a considerable increase in cost of care. Degradation of high-molecular-weight multimers of von Willebrand factor, occurring due to high shear stress and diminished arterial pulse amplitude, is believed to be the principal mechanism of GI bleeding in continuous-flow LVADs. 23 -25 The rate of GI bleeding in this study is similar to other studies. 26 -28 GI bleeding is a continuous risk, as the rate is evenly distributed between early and late follow-up (8% vs. 11%). Notably, event-free survival at 2 years was 77% as opposed to 81 ± 5% reported in the EU TRACE study. 29 In this context, a putative contribution of the aspirin-free antithrombotic protocol used in the EU TRACE trial for minimizing GI bleeding is yet to be elucidated in future investigations. Since significantly higher preservation of high-molecular-weight multimers of von Willebrand factor in HeartMate 3 has been reported previously, 5 lower bleeding rates would be expected. Interestingly, the GI bleeding rates observed in MOMENTUM 3 do not substantiate this assumption. One may hypothesize that this could be explained by collateral signal pathways, which may contribute to homeostasis and microvasculature dysregulations. Given the absence of pump thrombosis at 2 years, future safety studies focused on the refinement of reduced-intensity anticoagulation protocols are warranted. and one unidentified. Procedure-related strokes were associated with the following: (i) difficulty in placing the inflow conduit, (ii) anaphylaxis from contrast media for a lung computed tomography scan, and (iii) transcatheter aortic valve implantation. 8 Of note, procedure-related strokes may have been in part attributed to the initial learning curve, and the others may be addressed with improved patient management. As such, these do not necessarily represent ongoing risk in the future. The overall stroke rate of 24% at 2 years (with low stroke rates between the first and the . . second year), observed in this study, is comparable to other studies with 2-year follow-up that have overall stroke rates in the range of 16.2% to 29.7%. 13,21,30 -32 The higher early stroke rate might be reasonably explained by small numbers in the CE mark trial as well as by the learning curve during the course of the study. Nevertheless, this observation is of concern, albeit within the scope often observed in this difficult population. A previous publication by Mehra 33 presented a method to better understand the complex interactions of Figure 4 Adverse event profiles observed 2 years after implantation of the HeartMate 3 support in patients during the MOMENTUM 3 and CE Mark trials. These are not direct comparisons with variations in adverse event definitions and adjudications of events. Suspected cases of pump thrombosis were not confirmed. DLI, driveline infection; GI, gastrointestinal; RHF, right heart failure.
haemocompatibility-related adverse events by offering a comprehensive scoring system that is clinically relevant. When this scoring system was applied to the MOMENTUM 3 data at 6 months, although HeartMate 3 patients demonstrated a higher freedom from blood-related adverse events (primarily driven by absence of pump thrombosis and reduction in non-disabling strokes), disabling strokes continue to represent 35% of the overall score. This advantage of HeartMate 3 over HeartMate II has been solely due to the absence of pump thrombosis, whereas disabling strokes and the death due to haemocompatibility aetiology represented 43% of the overall score. This may be attributed to wide blood flow path in the HeartMate 3, which may paradoxically serve as an avenue for ingested material to reach the systemic circulation. Careful attention must be paid to address pre-pump thrombotic factors, such as left atrial appendage in atrial fibrillation and patent foramen ovale.
14 Conversely, the detailed analysis demonstrates the insignificance of blood pressure control on haemocompatibility-related outcomes in HeartMate 3, as opposed to centrifugal devices without full magnetic levitation.
21
Driveline infection
Driveline infection is a continuous risk over the course of LVAD support. A trend toward higher incidence of driveline infections observed with the HeartMate 3 compared to HeartMate II at 6 months in the MOMENTUM 3 trial has not attained statistical significance even at 2 years. 13, 22 Our observations from the initial clinical trial are consistent with the randomized data and confirm the probability of driveline infection in a quarter of the implanted population at 2-year follow-up. Presumably, painstaking comprehensive management of driveline infections or ultimately complete driveline elimination may additionally mitigate the stroke risk related to concomitant infection.
. 
Right heart failure
Right heart failure rates were favourable, with only two cases in which a right ventricular assist device was required following HeartMate 3 implantation. The incidence of late right heart failure was low (2/37; 5%), with both instances managed medically. This observation is consistent with other studies and demonstrates haemodynamic stability, without the need for frequent adjustments in pump speed.
13,34
Survival
The survival rate of 74% at 2 years with HeartMate 3 support mostly exceeds that of other recent trials 21, 30, 35 and is comparable to post-market registry reports as well as to the 2-year follow-up of the MOMENTUM 3 study, even though the initial shorter-term (6-month) survival rates appeared to be slightly higher. 36 -38 The CE mark study was performed a few months earlier than the MOMEN-TUM study, the results of which benefited the training of worldwide surgical teams. The slightly higher short-term survival rates may be attributed to surgical expertise, due to high volume surgical centre selection while higher long-term survival rates might indicate optimized postoperative anticoagulation and antiplatelet protocols used for patient follow-up and management.
Results suggest that improved survival rates are due to enhanced durability and haemocompatibility with this device.
13 Careful consideration is necessary when comparing these results to other clinical studies with durable continuous-flow LVADs because of the mix of BTT and DT indications, varied study protocols (including surgical techniques), and patient care protocols. The 2-year survival rate is 85% for BTT studies and 74% for DT. 33, 39, 40 In a recent report of a study involving all patients receiving durable support (n = 5942), with data taken from the International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support (IMACS) registry, the 6-month and 1-year survival rates were 86% and 80%, respectively.
11 Despite differences in the study protocols of other investigations, survival rates for this study are similar to other experiences.
Limitations
This study was limited by the non-randomized and non-controlled design and relatively small number of participants at 10 different centres. The trial had a novel design, including 'all-comers' with advanced stage heart failure, and thus did not distinguish patients by the intent for heart transplantation or lifetime support, making comparison with prior LVAD trials challenging.
Conclusion
Patients with advanced stage heart failure were effectively supported by the HeartMate 3 LVAS for durations of up to 2 years. Most patients experienced improved functional status and quality of life. As a first-in-human experience of HeartMate 3, survival rates and adverse event profiles were acceptable when compared with other clinical studies (Figure 4 ) such as those observed in the 2-year outcomes of the MOMENTUM 3 study, showing overall high post-implant survival rates across all the time-points and a low incidence of suspected pump thrombosis as well as device malfunction. 13 This may be attributed to reduced shear stress, reduced friction as well as intrinsic pulse design. 13 Adverse events with this device may be addressed by standardization and optimization of anticoagulation/antiplatelet protocols, antibiotic regimen, and further design enhancements. 5, 13, 29, 41 Ongoing clinical studies with longer-term data will help to better understand the haemocompatibility of this device.
